Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) saw a significant growth in short interest in November. As of November 15th, there was short interest totalling 13,950,000 shares, a growth of 42.9% from the October 31st total of 9,760,000 shares. Based on an average daily trading volume, of 2,490,000 shares, the short-interest ratio is […]
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) had its price target reduced by Canaccord Genuity Group from $7.00 to $6.00 in a report released on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 91.69% from the company’s previous […]
Taysha Gene Therapies (NASDAQ:TSHA – Free Report) had its price objective increased by Truist Financial from $2.00 to $6.00 in a research note published on Tuesday morning, Marketbeat Ratings reports. Truist Financial currently has a buy rating on the stock. A number of other brokerages have also recently commented on TSHA. Robert W. Baird raised […]
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) had its price objective lowered by stock analysts at Canaccord Genuity Group from $13.00 to $7.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 278.38% from […]
Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Rating) was the recipient of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 1,190,000 shares, a decline of 31.2% from the April 30th total of 1,730,000 shares. Based on an average daily trading volume, of 401,900 […]